Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

60%

3 trials in Phase 3/4

Results Transparency

0 of 1 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 4

2(50.0%)

Phase 2

1(25.0%)

Phase 3

1(25.0%)

4Total

Phase 4(2)

Phase 2(1)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials

NCT04880746Phase 3Unknown

Efficacy and Safety of Cladribine Combined With BEAC Pretreatment Regimen in the Treatment of Peripheral T-cell Lymphoma: a Multicenter Clinical Study

Role: collaborator

NCT03123887Completed

Evaluate the Hematological Remission Rates and Survival Among Chinese Adult Patients With B-precursor ALL

Role: lead

NCT02838992Phase 4Unknown

ATG Combined With Cyclophosphamide And Cord Blood Transfusion in Treating Patients With Severe Aplastic Anemia

Role: collaborator

NCT01328236Phase 2Unknown

Bortezomib in Combination With Liposomal Doxorubicin and Dexamethasone to Treat Plasma Cell Leukemia

Role: collaborator

NCT01249690Phase 4Unknown

Efficacy Study of PAD and TAD in Newly Diagnosed Multiple Myeloma

Role: collaborator

All 5 trials loaded